Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Rating Reaffirmed by Cantor Fitzgerald
Cantor Fitzgerald reaffirmed their overweight rating on shares of Mirum Pharmaceuticals (NASDAQ:MIRM – Free Report) in a research report sent to investors on Monday morning, Benzinga reports. The firm currently has a $50.00 target price on the stock. Other research analysts have also recently issued research reports about the stock. JMP Securities reaffirmed a market […]